Abstract:Abstract The elevated risk of Parkinson’s disease in patients with diabetes might be mitigated depending on the type of drugs prescribed to treat diabetes. Population data for risk of Parkinson’s disease in users of the newer types of drugs used in diabetes are scarce. We compared the risk of Parkinson’s disease in patients with diabetes exposed to thiazolidinediones (glitazones), glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, with the risk of Parkinson’s disease of users of any other oral glucose lowering drugs. A population-based, longitudinal, cohort study was conducted using historic primary care data from The Health Improvement Network. Patients with a diagnosis of diabetes and a minimum of two prescriptions for diabetes medications between January 2006 and January 2019 were included in our study. The primary outcome was the first recording of a diagnosis of Parkinson’s disease after the index date, identified from clinical records. We compared the risk of Parkinson’s disease in individuals treated with glitazones or DPP4 inhibitors and/or GLP-1 receptor agonists to individuals treated with other antidiabetic agents using a Cox regression with inverse probability of treatment weighting based on propensity scores. Results were analysed separately for insulin users. Among 100 288 patients [mean age 62.8 years (standard deviation 12.6)], 329 (0.3%) were diagnosed with Parkinson’s disease during the median follow-up of 3.33 years. The incidence of Parkinson’s disease was 8 per 10 000 person-years in 21 175 patients using glitazones, 5 per 10 000 person-years in 36 897 patients using DPP4 inhibitors and 4 per 10 000 person-years in 10 684 using GLP-1 mimetics, 6861 of whom were prescribed GTZ and/or DPP4 inhibitors prior to using GLP-1 mimetics. Compared with the incidence of Parkinson’s disease in the comparison group (10 per 10 000 person-years), adjusted results showed no evidence of any association between the use of glitazones and Parkinson’s disease [incidence rate ratio (IRR) 1.17; 95% confidence interval (CI) 0.76–1.63; P = 0.467], but there was strong evidence of an inverse association between use of DPP4 inhibitors and GLP-1 mimetics and the onset of Parkinson’s disease (IRR 0.64; 95% CI 0.43–0.88; P < 0.01 and IRR 0.38; 95% CI 0.17–0.60; P < 0.01, respectively). Results for insulin users were in the same direction, but the overall size of this group was small. The incidence of Parkinson’s disease in patients diagnosed with diabetes varies substantially depending on the treatment for diabetes received. The use of DPP4 inhibitors and/or GLP-1 mimetics is associated with a lower rate of Parkinson’s disease compared to the use of other oral antidiabetic drugs.

Diabetes drug slows development of Parkinson's disease

Decreased Risk of Parkinson's Disease in Diabetic Patients with Thiazolidinediones Therapy: an Exploratory Meta-Analysis.

Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study

Repurposing a diabetes drug to treat Parkinson's disease

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes

Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making?

Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease-A Meta-analysis of Randomized Outcome Trials

[Anti-diabetic drugs. Weight reduction as a favourable side effect]

Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson's Disease

Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease

Meta‐analysis of Association Between Newer Glucose‐Lowering Drugs and Risk of Parkinson's Disease

A New Treatment in Parkinson's Disease

Antihypertensive drugs may not delay the symptom progression of Parkinson's disease: A 2-year follow-up study

Obesity drugs have another superpower: taming inflammation

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study

DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease

Advances in the anti-Parkinson's disease drugs

How rival weight-loss drugs fare at treating obesity, diabetes and more

Prospects for Disease Slowing in Parkinson Disease

Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes

The use of hypoglycemic drugs in Parkinson's disease: an updated meta-analysis of randomized controlled trials